ABSTRACT
Ceftobiprole, formerly BAL 9141 or RO 63-9141, is a novel pyrrolidinone-3-ylidene-methyl cephalosporin with clinically demonstrable activity against methicillin-resistant Staphylococcus aureus (MRSA). Ceftobiprole medocaril (BAL 5788, JNJ 30982081, JNJ 30982081, RO 65-5788, RO 655788) is a water-soluble prodrug of ceftobiprole. This antibiotic is the first beta-lactam antibiotic to have In vitro activity against MRSA and vancomycin-resistant S. aureus (VRSA). Although not yet available in the USA, ceftobiprole has been approved for use in Canada and a number of European countries.
